

Charbel Moussa Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3359321/publications.pdf>

Version: 2024-02-01

38
papers

2,063
citations

304743

22
h-index

361022

35
g-index

41
all docs

41
docs citations

41
times ranked

3000
citing authors

#	ARTICLE	IF	CITATIONS
1	Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2017, 14, 1.	7.2	544
2	Resveratrol for Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2017, 1403, 142-149.	3.8	198
3	Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. <i>Journal of Parkinson's Disease</i> , 2016, 6, 503-517.	2.8	193
4	Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. <i>Journal of Molecular Medicine</i> , 2014, 92, 373-386.	3.9	122
5	Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease. <i>JAMA Neurology</i> , 2020, 77, 309.	9.0	108
6	Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. <i>Annals of Neurology</i> , 2020, 88, 183-194.	5.3	73
7	Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00470.	2.4	71
8	Ubiquitination Increases Parkin Activity to Promote Autophagic α -Synuclein Clearance. <i>PLoS ONE</i> , 2013, 8, e83914.	2.5	69
9	Tyrosine kinase inhibition facilitates autophagic SNCA/ α -synuclein clearance. <i>Autophagy</i> , 2013, 9, 1249-1250.	9.1	53
10	Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 1-11.	5.9	45
11	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1131-1136.	4.1	44
12	Discoïdin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. <i>Journal of Neuroimmunology</i> , 2017, 311, 1-9.	2.3	43
13	Tau deletion impairs intracellular β -amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. <i>Molecular Neurodegeneration</i> , 2014, 9, 46.	10.8	42
14	Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration. <i>Drugs in R and D</i> , 2019, 19, 149-166.	2.2	42
15	Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. <i>Journal of the Neurological Sciences</i> , 2018, 391, 90-99.	0.6	39
16	Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. <i>Human Molecular Genetics</i> , 2014, 23, 4960-4969.	2.9	36
17	Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis. <i>Journal of Neurochemistry</i> , 2014, 129, 350-361.	3.9	32
18	Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 740-749.	3.9	32

#	ARTICLE	IF	CITATIONS
19	Tyrosine kinase inhibition reverses <sc>TDP</sc>â€³ effects on synaptic protein expression, astrocytic function and amino acid disâ€homeostasis. Journal of Neurochemistry, 2016, 139, 610-623.	3.9	30
20	Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases. Human Molecular Genetics, 2020, 29, 2882-2898.	2.9	28
21	Parkin prevents cortical atrophy and AÎ²-induced alterations of brain metabolism: 13C NMR and magnetic resonance imaging studies in AD models. Neuroscience, 2012, 225, 22-34.	2.3	22
22	Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 425-441.	2.6	21
23	Parkin Attenuates Wild-Type Î±, Modification in the Presence of Î²-Amyloid and Î±-Synuclein. Journal of Molecular Neuroscience, 2009, 37, 25-36.	2.3	19
24	The ubiquitin ligase parkin modulates the execution of autophagy. Autophagy, 2011, 7, 919-921.	9.1	18
25	Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and AÎ²1-42 gene transfer models. Experimental Neurology, 2014, 251, 127-138.	4.1	13
26	Regulatory Role of Ubiquitin Specific Protease-13 (USP13) in Misfolded Protein Clearance in Neurodegenerative Diseases. Neuroscience, 2021, 460, 161-166.	2.3	13
27	Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology. Metabolites, 2021, 11, 622.	2.9	12
28	CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease. Neurology: Genetics, 2021, 7, e633.	1.9	12
29	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
30	Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	6.2	9
31	Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	6
32	Can sex influence the neurocognition of language? Evidence from Parkinson's disease. Neuropsychologia, 2020, 148, 107633.	1.6	5
33	Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1571-1579.	1.4	4
34	Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Diseaseâ€”Reply. JAMA Neurology, 2020, 77, 1039.	9.0	2
35	Could cancer drugs be repurposed for use in Parkinsonâ€™s and Alzheimerâ€™s?. Expert Review of Neurotherapeutics, 2016, 16, 1335-1336.	2.8	0
36	Authorâ€™s Reply to Segura-Aguilar: Autophagosome maturation not autophagy induction is impaired in neurodegeneration. CNS Drugs, 2018, 32, 687-688.	5.9	0

#	ARTICLE	IF	CITATIONS
37	Reply to "Cardiovascular Safety of Nilotinib in Alzheimer's Disease" Annals of Neurology, 2021, 89, 196-197.	5.3	0
38	Autophagy in Neurodegenerative Diseases. Cancer Drug Discovery and Development, 2019, , 197-212.	0.4	0